Venn Therapeutics, a privately held immuno-oncology company focused on developing novel, early-stage cancer therapies, announced today that Mr. Joseph Lobacki has been appointed to its board of directors.
Mr. Lobacki has 30 plus years of experience working within the pharma and biotech industry, which have been marked by an impressive history of success and delivering significant shareholder value. Notably, Mr. Lobacki was the chief commercial officer at Medivation prior to its acquisition by Pfizer for $14.0B in September, 2016. Mr. Lobacki was also the senior vice president and general manager for Genzyme’s transplant and oncology division, prior to its acquisition by Sanofi for $20.0B in 2011. He has a proven track record of delivering business results while managing large and complex pharmaceutical divisions.
Currently, Mr. Lobacki serves as the interim CEO and COO of Crestovo LLC, a leader in microbiome technology. He holds a B.S. in biology from Boston College and a B.S. in pharmacy from Massachusetts College of Pharmacy. Mr. Lobacki is based in Boston, MA.
“We welcome Joseph to our fast growing team at Venn Therapeutics. His rich experience and leadership in pharmaceutical company operations, mergers and acquisition, oncology and strategic consulting make his addition to the board a big positive for our continued growth. Venn intends to deliver significant shareholder value by focusing on tomorrow’s medicines for cancer patients and add to the current medical arsenal against cancer” said Venn CEO, Sam Shrivastava.
Mr. Lobacki added, “I am excited to join an innovative team at Venn Therapeutics. Immuno-oncology is a very promising area for drug development and is leading to a better and durable outcome for some patients. Venn has built a compelling pipeline poised to expand the patient population benefiting from immuno-oncology and is well positioned for future growth and success.”
For more information about Venn Therapeutics, please visit:
About Venn Therapeutics:
Venn Therapeutics is an immuno-oncology company focused on developing novel, best-in-class drugs such as a STING agonist and β-catenin inhibitors, which transform tumor-resident innate immune cells to an anti-tumor phenotype reversing the immunosuppressive microenvironment found within tumors. Venn believes this approach will expand the number of patients who can be effectively treated with immuno-oncology modalities such as PD-1/PD-L1 checkpoint inhibitors.